Standard BioTools Faces Nasdaq Delisting Notice as Stock Slips Below $1
LAB sits 19% above its 52-week low of $0.703 on light trading volume (0.3× avg).
Summary
Standard BioTools received a Nasdaq delisting notice on July 22, 2026, after its stock traded below $1.00 for 30 consecutive business days. The company has until January 19, 2027, to regain compliance, potentially through a reverse stock split or share price recovery.
Key Events · Legal and Risk Events · LAB
-
Nasdaq Delisting Notice Received
On July 22, 2026, Standard BioTools received a notice from Nasdaq for failing to meet the $1.00 minimum bid price requirement after 30 consecutive business days below the threshold.
-
180-Day Compliance Period
The company has until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
-
Potential Reverse Stock Split
If the share price does not recover, the company may implement a reverse stock split to meet the requirement, which could be executed during an additional 180-day period if it transfers to the Nasdaq Capital Market.
-
Merger Context Adds Urgency
The delisting notice arrives amid a pending reverse merger with Treeline Biosciences, announced in June 2026, which could be jeopardized if the stock is delisted before closing.
Analysis · LAB · Life Sciences
Nasdaq has put Standard BioTools on notice for failing to maintain a $1.00 minimum bid price, starting a 180-day clock to regain compliance. The warning lands just weeks after the company unveiled a transformative reverse merger with Treeline Biosciences and reported a strong cash position from its SomaScan divestiture. While trading continues unaffected for now, the notice heightens pressure on the merger timeline and raises the specter of a reverse stock split if the share price doesn't recover on its own. The stock closed below $1 for 30 consecutive business days, signaling market skepticism despite the pending merger's potential.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 44.3% of the 601 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LAB was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $326.2M. The 52-week trading range was $0.70 to $1.72. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.